TY - JOUR T1 - Brain Metastasis in a Patient with a Sarcomatoid Variant RCC with Well-controlled Extracerebral Metastases by Temsirolimus JF - Anticancer Research JO - Anticancer Res SP - 3443 LP - 3447 VL - 32 IS - 8 AU - NOBUYUKI KIKUNO AU - TAKAFUMI KENNOKI AU - HIRONORI FUKUDA AU - YUICHI MATSUMOTO AU - KUNIKO TSUNOYAMA AU - SHINICHI BAN AU - HIDEAKI SATOH AU - OSAMU RYOJI Y1 - 2012/08/01 UR - http://ar.iiarjournals.org/content/32/8/3443.abstract N2 - Background: The sarcomatoid variant of metastatic renal cell carcinoma (RCC) has often an aggressive course and a poor prognosis, particularly when accompanied with brain metastasis. Case Report: We describe the case of a patient with sarcomatoid variant RCC in whom brain metastasis was observed as a new lesion during treatment with temsirolimus, despite other extracerebral metastatic lesions being well-controlled and progression-free. Results: This discrepancy between the effectiveness of temsirolimus for extracerebral metastases and the simultaneous progression of brain metastases of RCC raises a concern that while vascular endothelial growth factor (VEGF)-targeted therapy may have clinical efficacy, it may also carry a risk for new brain metastases due to weakening of the structure of the blood brain barrier. Conclusion: This case indicates that computed tomography monitoring of the brain should be regularly performed during VEGF-targeted therapy in patients with sarcomatoid variant RCC, even if brain metastases are absent and extracerebral metastatic lesions are well controlled. ER -